Skip to content
AnalystLens

Neurocrine Biosciences Annual Report, Year Ended Dec 31, 1998

Filing Date
Filed March 31, 1999
Period End
December 31, 1998
Security
NBIX
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Sep ’19Sep ’19
  3. Material agreement8-K · Nov ’21Nov ’21
  4. Leadership change8-K · Nov ’25Nov ’25

Summary

Summary of the 10-K filed March 31, 1999. Cited figures are marked; the original filing is the authoritative source.

Neurocrine Biosciences, Inc. filed this Form 10-K for the fiscal year ended December 31, 1998, describing itself as a neuroscience company focused on discovering and developing therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases.

Total revenues were $16.0 milliona in 1998, down from $26.1 million in 1997, while research and development expenses rose to $21.8 million and a $4.9 million write-off of acquired in-process R&D related to the Northwest NeuroLogic acquisition and licenses was taken. The company reported a net loss of $20.0 million, or $1.10 per share, compared with net income of $5.1 million in 1997, and its accumulated deficit grew to $24.9 million. The filing states the company has no product revenues and expects to rely on strategic alliances with Janssen, Novartis, Eli Lilly and Wyeth-Ayerst, and that existing capital resources together with alliance payments will be sufficient at least through 2000.

The company's pipeline includes five clinical programs: a CRF receptor antagonist in Phase II with Janssen for anxiety and depression, an altered peptide ligand for multiple sclerosis in Phase II with Novartis, an IL-4 Fusion Toxin in Phase I/II for glioblastoma, a GABA receptor subtype agonist (NBI-34060) for insomnia, and an altered peptide ligand for Type I diabetes in Phase I. Cash, cash equivalents and short-term investments totaled $62.7 millionb at year-end 1998, down from $75.1 million in 1997. The filing also reports that the DHEA neurosteroid program was discontinued in March 1999 after a Phase II/III trial failed to show a difference from placebo, and that a March 2, 1999 collaboration with Wyeth-Ayerst on excitatory amino acid transporters is valued at up to $78 million.

The filing discloses material risks, including dependence on corporate partners that can terminate their agreements, a third-party patent application that could affect Janssen's lead CRF compound, and reliance on contract manufacturers. The company had 149 employees as of December 31, 1998.

Key Highlights

  1. Total revenues were $16.0 million in 1998, compared with $26.1 million in 1997.
  2. Net loss was $20.0 million, or $1.10 per share, versus net income of $5.1 million, or $0.30 per share, in 1997.
  3. Research and development expenses increased to $21.8 million, and a $4.9 million write-off of acquired in-process R&D was recorded.
  4. Cash, cash equivalents and short-term investments were $62.7 million at December 31, 1998, down from $75.1 million a year earlier.
  5. Five clinical programs are in development, including a CRF antagonist in Phase II with Janssen for anxiety and depression and an altered peptide ligand in Phase II with Novartis for multiple sclerosis.
  6. The DHEA neurosteroid program was discontinued in March 1999 after a Phase II/III trial showed no efficacy difference from placebo.
  7. A March 2, 1999 collaboration with Wyeth-Ayerst on excitatory amino acid transporters is valued at up to $78 million.

Frequently Asked Questions

  1. Does Neurocrine Biosciences currently generate product revenue?

    No. The filing states the company has not generated any revenues from product sales and does not expect product revenues for the foreseeable future. Its revenues come from sponsored research, milestones and license fees under strategic alliances.

  2. How much cash does the company have and is it expected to be sufficient?

    Cash, cash equivalents and short-term investments totaled $62.7 million at December 31, 1998. The company believes this, together with interest income and future alliance payments, will be sufficient for its funding requirements at least through the year 2000, though it does not assure that this will be enough to conduct programs as planned.

  3. Why did the net loss increase in 1998?

    Revenues fell to $16.0 million from $26.1 million, research and development spending rose to $21.8 million, and the company recorded a $4.9 million in-process R&D write-off. It also booked $7.2 million of equity losses and adjustments related to Neuroscience Pharma, Inc., including a $3.8 million write-down of its investment.

  4. What are the key risks tied to the company's partners?

    The company depends on corporate partners such as Janssen, Novartis, Eli Lilly and Wyeth-Ayerst to fund programs and advance compounds. Each alliance can be terminated by the partner, and the filing says any delay or termination could materially affect the business.

  5. What patent risk affects the lead CRF program?

    A third-party patent application outside the United States claims a genus of compounds that includes Janssen's lead CRF candidate and appears to predate the Company and Janssen filings. Janssen may be unable to commercialize the lead compound in countries where the patent issues and may need to select a new lead, which could delay milestone and royalty income.